GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » RIV Capital Inc (XCNQ:RIV) » Definitions » Debt-to-EBITDA

RIV Capital (XCNQ:RIV) Debt-to-EBITDA

: -6.55 (As of Sep. 2023)
View and export this data going back to 2018. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

RIV Capital's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was C$1.58 Mil. RIV Capital's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was C$158.35 Mil. RIV Capital's annualized EBITDA for the quarter that ended in Sep. 2023 was C$-24.43 Mil. RIV Capital's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -6.55.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for RIV Capital's Debt-to-EBITDA or its related term are showing as below:

XCNQ:RIV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.39   Med: -0.34   Max: 0
Current: -3.39

XCNQ:RIV's Debt-to-EBITDA is ranked worse than
100% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs XCNQ:RIV: -3.39

RIV Capital Debt-to-EBITDA Historical Data

The historical data trend for RIV Capital's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RIV Capital Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Premium Member Only - -0.01 - -1.74 -0.68

RIV Capital Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.19 -6.67 -1.32 -5.59 -6.55

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, RIV Capital's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RIV Capital Debt-to-EBITDA Distribution

For the Drug Manufacturers industry and Healthcare sector, RIV Capital's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where RIV Capital's Debt-to-EBITDA falls into.



RIV Capital Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

RIV Capital's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.445 + 149.5) / -223.632
=-0.67

RIV Capital's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.578 + 158.351) / -24.432
=-6.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.


RIV Capital  (XCNQ:RIV) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


RIV Capital Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of RIV Capital's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


RIV Capital (XCNQ:RIV) Business Description

Traded in Other Exchanges
Address
40 King Street West, Suite 2504, Toronto, ON, CAN, M5H 3Y2
RIV Capital Inc is a venture capital investment and operating platform structured to pursue investment opportunities in the cannabis sector. The company has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the cannabis sector. The investments take the form of production-linked royalties, secured debt, newly formed joint ventures, and a variety of equity and equity-linked instruments.